Baycrest

Baycrest_General Stewardship Report_June_2024_V17-online

Baycrest Health Sciences & Baycrest Foundation Publications

Issue link: http://baycrest.uberflip.com/i/1522955

Contents of this Issue

Navigation

Page 16 of 35

17 BAYCREST | 2024 2022 2023 2024 2021 2019 2020 The Virtual Behavioural Medicine program expands our reach to help dementia patients and reduce wait times. Doctors assess patients remotely and prescribe treatments that keep them at home longer. Possibilities by Baycrest, a new, leading-edge memory care program for people with advanced dementia, ensures they can live full lives as much as possible. Baycrest@Home, an innovative program, helps older adults stay in their homes longer and lends support to caregivers. Baycrest Academy maximizes our impact with increased collaboration in knowledge discovery and dissemination, amplifying our reach and influence. The Canadian Consortium on Neurodegeneration in Aging moves its scientific headquarters to Baycrest. CCNA, Canada's largest national dementia research initiative, brings together researchers who work to treat and prevent dementia. The Bresver Neuromodulation & Therapeutics Program is launched to investigate non-invasive neuromodulation strategies, as one of the most promising treatments for Alzheimer's disease. The Anne & Allan Bank Centre for Clinical Research Trials is established and positioned at the forefront of dementia research. As of 2024, it boasts the largest number of ongoing therapy and intervention trials in Canada to treat and prevent dementia. Baycrest starts building the Pamela & Paul Austin AI Platform to incorporate artificial intelligence in the delivery of timely diagnosis and care for patients with cognitive difficulties.

Articles in this issue

view archives of Baycrest - Baycrest_General Stewardship Report_June_2024_V17-online